A recent study comparing standard regimens of doxorubicin and ifosfamide vs gemcitabine(G) and docetaxel(D) showed positive trends with the less toxic GD regimen. There was a trend towards fewer hospitalizations from side effects of treatment and also a trend to longer disease free survival (DFS) for patients who received GD regimen. More works needs to be done to see if this is the best option for the high-risk patient. Only 80 patients were evaluated between 2004 and 2012. To read more go to the complete reference below:
Eur J Cancer. 2015 Sep;51(13):1794-802.